You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
News items for the week of Feb. 22, 2021.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.
The UK's Medicines and Healthcare products Regulatory Agency approved the agent together with trastuzumab and chemo based on the Phase II HER2CLIMB trial.
The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.
Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.
News items for the week of Feb. 15, 2021.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
The grant will fund an investigation into long noncoding RNA and the role it plays in differing prognoses between Black and white breast cancer patients.
The MHRA relied on objective response rates in previously treated, HER2-positive patients in the DESTINY-Breast01 trial to make its decision on the drug.